Calder is a private biotechnology company applying proprietary technologies to develop conformationally locked, improved subunit vaccine immunogens. The company’s technologies enhance the performance of these products by stabilizing their conformations, which then better represent the 3-D structure of these proteins on the surface of the pathogen, and therefore give rise to more protective antibody responses. Calder is collaborating with several organizations to develop products and technologies in this space, including the Vaccine Research Center/NIAID, the University of Texas (Austin), PATH, Vanderbilt , the University of Pittsburgh, the University of Miami.